Navigation Links
Queen's scientists develop 'magic bullet' nanomedicine for Acute Lung Injury
Date:5/14/2013

Researchers at Queen's University Belfast have devised a 'magic bullet' nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.

There are 15,000 cases of ALI every year in the UK. The main causes are road traffic accidents and infections, and many with the condition die as a result of lung failure.

ALI patients can become critically ill and develop problems with breathing when their lungs become inflamed and fill with fluid. These patients frequently require ventilators to aid breathing within an ICU hospital unit. An ICU bed costs the NHS in excess of 1800 per day.

There are currently no effective treatments for this serious condition, but in a joint collaboration between the School of Pharmacy and Centre for Infection and Immunity at Queen's, a team of scientists and clinicians have developed a new drug that could revolutionise clinical management of patients in intensive care units.

Their new drug is a nanoparticle, measuring around one billionth of a metre. The patient can inhale it, taking the drug directly into the lungs and to the point of inflammation. Current treatments are unable to target directly the inflammation and can result in unpleasant side effects.

Speaking about the development, Professor Chris Scott from the School of Pharmacy, who is leading the research, said: "Nanoparticles are perhaps one of the most exciting new approaches to drug development. Most research in the area focuses on how the delivery of drugs to the disease site can be improved in these minute carriers. Our own research in this area focuses on how nanoparticles interact with cells and how this can be exploited to produce therapeutic effects both in respiratory disease and cancer."

The new nanoparticle from Queen's has a surface which allows it to recognize and bind to immune cells called macrophages in the lungs - key to the uncontrolled inflammation that occurs in ALI. This binding induces a rapid reduction in the inflammation, and has the potential to prevent the damaging effects that will otherwise occur in the lungs of ALI patients.

The project is developing the new nanomedicine towards clinical evaluation within the next three years, and is currently sponsored by a 505,000 grant for two years from the Medical Research Council Developmental Pathway Funding Scheme.

Professor Danny McAuley from the Centre for Infection and Immunity, a partner in developing the new nanomedicine, added:

"This funding allows us to evaluate a completely novel therapeutic approach to the treatment of ALI and if successful, this nanomedicine could also have application in other common lung disorders such as COPD and Cystic Fibrosis."


'/>"/>

Contact: Claire O'Callaghan
c.ocallaghan@qub.ac.uk
Queen's University Belfast
Source:Eurekalert

Related medicine news :

1. Block O'Toole & Murphy, LLP Recovers $4,650,000 For Construction Laborer Who Fell In Queens Warehouse
2. Queens University of Charlotte Introduces Online Master of Science in Nursing
3. Independence Residences Inc. Announces Affiliation with Queens Parent Resource Center (QPRC)
4. Scientists Discover More Genetic Clues to Testicular Cancer
5. Advocacy Group Awards $300,000 to Young Scientists in Search of a Cure for Bladder Cancer
6. Scientists define a new mechanism leading to tumor hypoxia
7. Scientists Explore Secrets of the Well-Hit Fastball
8. Monell scientists identify critical link in mammalian odor detection
9. Duke scientists build a living patch for damaged hearts
10. Scientists revolutionize the creation of genetically altered mice to model human disease
11. Scientists Pinpoint Most Major Genes Behind Deadly Blood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: